BODIPYI
Based on 1 Customer Validation
BODIPYI is the a BODIPY derivative. BODIPYI reveals a high O2 quantum yield and exhibits phototoxicity that inhibits HeLa with an IC50 of 0.6 μg/mL. BODIPYI nanoarticles can be taken up by HeLa, producing fluorescence signals in the cells, and can be used as cell imaging agent. BODIPYI nanoarticles exhibit antitumor efficacy in mouse models.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1083009-44-2
- Formule: C19H17BF2I2N2
- Masse moléculaire:575.97
-
Stockage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEp-2 | IC50 |
>400 μM
Compound: 1a
|
Dark toxicity in human Hep2 cells after 24 hrs by Cell Titre Blue assay
Dark toxicity in human Hep2 cells after 24 hrs by Cell Titre Blue assay
|
[PMID: 23928070] |
| HEp-2 | IC50 |
27 μM
Compound: 1a
|
Phototoxicity in human Hep2 cells incubated for 24 hrs followed by 1.5 J/cm'2 light irradiation for 20 mins measured after 24 hrs by Cell Titre Blue assay
Phototoxicity in human Hep2 cells incubated for 24 hrs followed by 1.5 J/cm'2 light irradiation for 20 mins measured after 24 hrs by Cell Titre Blue assay
|
[PMID: 23928070] |
Chemical Information
-
CAS No. 1083009-44-2
-
Appearance Solid
-
Masse moléculaire 575.97
-
Formule C19H17BF2I2N2
-
SMILES
CC(C(I)=C1C)=C(N1[B-]2(F)F)C(C3=CC=CC=C3)=C4[N+]2=C(C)C(I)=C4C
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Protocole
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
Pureté et documentation
-
Fiche technique (286 KB)
-
SDS (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
BODIPYI Related Classifications
HY-W112239 Related Classifications
Powered by Bioz